A brief overview is made of the main oncogenes and oncosuppressors currently being studied in bladder tumours. Although many data are available, only the altered p53 dosage seems to have any short-term clinical application.
SandbergA.A.BergereC.S.: Review of chromosome studies in urological tumours. II. Cystogenetics and molecular genetics of bladder cancer. J. Urol., 151: 545–560, 1994.
3.
CranidisA.DelakasD.AnezinisP.AgnantisN.HaliassosA.SpandidosD.A.: Expression of the ras and myc protc-oncogenes in bladder tumours and its correlation with staging and grading of the tumours. Acta Urol. Ital., 10(3): 237–242, 1996.
4.
GonteroP.CasettaG.TizzaniA.: La determinazione immunoistochimica della proteina p53 nei tumori uroteliali. Luci e ombre sulla sua utilità come indice prognostico. Revisione della Letteratura. Urologia Pratica, 4: 161–170, 1997.
5.
Van VeltovenL.BrausiM.BouffiouxC.HoltlW.KurthK.H.Van der MeijdenA.P.M.: Recent developments of basic research in superficial transitional cell carcinoma of the bladder. Acta Urol. Ital., 10(3): 193–198, 1996.
